Xinjian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinjian Li has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Zhimin Lu
Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China
14 shared publications - Lin Tan
College of Biomass Science and Engineering, Key Laboratory of Biomass Fibers for Medical Care in Textile Industry, Sichuan University, Chengdu 610065, China
11 shared publications - Philip Lorenzi
City of Hope National Medical Center
11 shared publications - Qian Xu
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China
11 shared publications - Qingsong Cai
Zhongxing Telecom Equipment Company Ltd., Nanjing, China
11 shared publications Yanhua Zheng
11 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1852
Itaconic Acid Directly Binds to the Cysteine Residue of PurF: A Novel Mechanism for Inhibiting Purine Metabolism in Porcine Pathogenic Escherichia coli
Itaconic acid has been reported to possess anti-inflammatory and antibacterial properties. However, its specific mechanisms of action against pathogenic bacteria, especially in the context of purine metabolism, remain poorly understood. Here, we investigate the impact of itaconic acid on the purine metabolism of PCN033, a highly pathogenic porcine extraintestinal pathogenic Escherichia coli (ExPEC) strain. Our in vitro and in vivo experiments demonstrated that itaconic acid significantly inhibited the proliferation of PCN033. Multi-omics analyses, including transcriptome and metabolome sequencing, revealed that itaconic acid severely disrupted the purine metabolism pathway of PCN033. Further mechanistic studies identified PRPP amidotransferase (PurF), a key enzyme in de novo purine synthesis, as a direct target of itaconic acid. Molecular docking and click chemistry experiments provided compelling evidence that itaconic acid specifically binds to the second cysteine residue (2C) of PurF, leading to the inhibition of its enzymatic activity. These data reveal a novel and critical mechanism by which itaconic acid exerts its antibacterial effects in response to bacterial infection. Importantly, our in vivo data show that supplementation with itaconic acid alleviated weight loss, organ damage, and inflammatory responses induced by PCN033 infection in mice and nursery pigs. These novel findings enhance our understanding of the antibacterial mechanisms of itaconic acid. Supplementation with itaconic acid could serve as a therapeutic strategy for treating pathogenic bacterial infections in humans and other animals.
- 20 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1852
Open AccessItaconic Acid Directly Binds to the Cysteine Residue of PurF: A Novel Mechanism for Inhibiting Purine Metabolism in Porcine Pathogenic Escherichia coli
Itaconic acid has been reported to possess anti-inflammatory and antibacterial properties. However, its specific mechanisms of action against pathogenic bacteria, especially in the context of purine metabolism, remain poorly understood. Here, we investigate the impact of itaconic acid on the purine metabolism of PCN033, a highly pathogenic porcine extraintestinal pathogenic Escherichia coli (ExPEC) strain. Our in vitro and in vivo experiments demonstrated that itaconic acid significantly inhibited the proliferation of PCN033. Multi-omics analyses, including transcriptome and metabolome sequencing, revealed that itaconic acid severely disrupted the purine metabolism pathway of PCN033. Further mechanistic studies identified PRPP amidotransferase (PurF), a key enzyme in de novo purine synthesis, as a direct target of itaconic acid. Molecular docking and click chemistry experiments provided compelling evidence that itaconic acid specifically binds to the second cysteine residue (2C) of PurF, leading to the inhibition of its enzymatic activity. These data reveal a novel and critical mechanism by which itaconic acid exerts its antibacterial effects in response to bacterial infection. Importantly, our in vivo data show that supplementation with itaconic acid alleviated weight loss, organ damage, and inflammatory responses induced by PCN033 infection in mice and nursery pigs. These novel findings enhance our understanding of the antibacterial mechanisms of itaconic acid. Supplementation with itaconic acid could serve as a therapeutic strategy for treating pathogenic bacterial infections in humans and other animals.
- Open Access
- 22 January 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Itaconate and its derivatives ameliorate autoimmunity by suppressing Th17 cells via regulating mitophagy
Itaconate (ITA) originates by decarboxylation of cis-aconitate catalyzed by the enzyme aconitate decarboxylase 1. It has immunomodulatory properties, but i
- 22 January 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessItaconate and its derivatives ameliorate autoimmunity by suppressing Th17 cells via regulating mitophagy
Itaconate (ITA) originates by decarboxylation of cis-aconitate catalyzed by the enzyme aconitate decarboxylase 1. It has immunomodulatory properties, but i
- Open Access
- 16 July 2025
- Published by Elsevier in Cell Reports Methods
- Vol. 5 (7) , 101106
A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy
- 16 July 2025
- Published by Elsevier in Cell Reports Methods
- Vol. 5 (7) , 101106
Open AccessA fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy
- Open Access
- 7 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (10) , eadq4266
Isocyanic acid–mediated NLRP3 carbamoylation reduces NLRP3-NEK7 interaction and limits inflammasome activation
Isocyanic acid, as a reactive metabolite synthesized by the enzyme LACC1, can carbamoylate the ε-amino group of lysine residues in proteins. However, the role of isocyanic acid in inflammatory response remains elusive. Herein, we reveal that lipopolysaccharide stimulation increases LACC1-dependent isocyanic acid production, which attenuates inflammation by limiting the NLRP3 inflammasome activation in macrophages primed with lipopolysaccharide for 8 hours. Mechanistically, isocyanic acid directly carbamoylates NLRP3 at lysine-593 to disrupt NLRP3-NEK7 interaction, a key step in assembly of active NLRP3 inflammasome. Abrogation of isocyanic acid biosynthesis by LACC1 / Lacc1 knockout or expression of K593 carbamoylation (K593ca)–deficient NLRP3 mutant promotes macrophagic inflammatory response in vitro. Furthermore, Lacc1 −/− mice and mice harboring K593ca-deficient NLRP3 mutation manifest exacerbated inflammatory response in vivo. Hence, our findings identify isocyanic acid as an endogenous immunoregulatory metabolite that limits NLRP3-driven inflammation and provide valuable insights into the regulation of NLRP3 inflammasome activation, governed by metabolites.
- 7 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (10) , eadq4266
Open AccessIsocyanic acid–mediated NLRP3 carbamoylation reduces NLRP3-NEK7 interaction and limits inflammasome activation
Isocyanic acid, as a reactive metabolite synthesized by the enzyme LACC1, can carbamoylate the ε-amino group of lysine residues in proteins. However, the role of isocyanic acid in inflammatory response remains elusive. Herein, we reveal that lipopolysaccharide stimulation increases LACC1-dependent isocyanic acid production, which attenuates inflammation by limiting the NLRP3 inflammasome activation in macrophages primed with lipopolysaccharide for 8 hours. Mechanistically, isocyanic acid directly carbamoylates NLRP3 at lysine-593 to disrupt NLRP3-NEK7 interaction, a key step in assembly of active NLRP3 inflammasome. Abrogation of isocyanic acid biosynthesis by LACC1 / Lacc1 knockout or expression of K593 carbamoylation (K593ca)–deficient NLRP3 mutant promotes macrophagic inflammatory response in vitro. Furthermore, Lacc1 −/− mice and mice harboring K593ca-deficient NLRP3 mutation manifest exacerbated inflammatory response in vivo. Hence, our findings identify isocyanic acid as an endogenous immunoregulatory metabolite that limits NLRP3-driven inflammation and provide valuable insights into the regulation of NLRP3 inflammasome activation, governed by metabolites.
- Open Access
- 22 November 2024
- Published by Elsevier in Cell Insight
- Vol. 4 (1) , 100224
The cell autonomous and non-autonomous roles of itaconate in immune response
- 22 November 2024
- Published by Elsevier in Cell Insight
- Vol. 4 (1) , 100224
Open AccessThe cell autonomous and non-autonomous roles of itaconate in immune response
- 7 August 2024
- Published by Elsevier in Developmental Cell
- Vol. 59 (21) , 2807-2817.e8
Itaconate uptake via SLC13A3 improves hepatic antibacterial innate immunity
- 7 August 2024
- Published by Elsevier in Developmental Cell
- Vol. 59 (21) , 2807-2817.e8
Itaconate uptake via SLC13A3 improves hepatic antibacterial innate immunity
- 4 January 2024
- Published by Elsevier in Cell Metabolism
- Vol. 36 (3) , 498-510.e11
ABCG2 is an itaconate exporter that limits antibacterial innate immunity by alleviating TFEB-dependent lysosomal biogenesis
- 4 January 2024
- Published by Elsevier in Cell Metabolism
- Vol. 36 (3) , 498-510.e11
ABCG2 is an itaconate exporter that limits antibacterial innate immunity by alleviating TFEB-dependent lysosomal biogenesis